Pharmacokinetic studies of two compounds in non-naive cynomolgus monkeys, using both oral and intravenous routes of administration, with bioanalyses in plasma conducted in triplicate. Pharmaron,…
Ended Purchase Order Awarded Last action
- Contract number
- 75N95024P00536
- Awardee
-
Pharmaron, Inc. UEI L8NQAFSTPSY9
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $24,320
Award facts
- Opportunity
-
- 75N95024Q00504 Solicitation number
- Contract value 100% obligated
- $24,320.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541380 Testing Laboratories and Services
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- China
Award details come from SAM.gov/FPDS.
About this award
This is a firm fixed-price purchase order contract awarded by the National Center for Advancing Translational Sciences (NCATS), a civilian agency under the National Institutes of Health (NIH), to Pharmaron, Inc. The contract is valued at $24,320.00 and does not have a set-aside designation.
The contract is for pharmacokinetic studies of two compounds in non-naive cynomolgus monkeys, using both oral and intravenous routes of administration, with bioanalyses in plasma conducted in triplicate. This work supports NCATS' drug discovery and development pipeline, as Pharmaron, a global contract research organization (CRO), specializes in providing preclinical research services to government agencies and pharmaceutical/biotechnology companies. The contract has a period of performance through November 18, 2024.
Description
Pharmacokinetic studies of two compounds in non-naive cynomolgus monkeys, using both oral and intravenous routes of administration, with bioanalyses in plasma conducted in triplicate. Pharmaron, INC.:1208250 [24-007191]
Quick answers
Who was awarded contract 75N95024P00536?
75N95024P00536 was awarded to Pharmaron, Inc. by National Institute on Drug Abuse (National Institutes of Health) on September 23, 2024.
How much is contract 75N95024P00536 worth?
The government has obligated $24,320 on 75N95024P00536.
Which agency awarded contract 75N95024P00536?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95024P00536, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Was contract 75N95024P00536 competed?
The extent of competition for 75N95024P00536 was competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award